AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03895476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound covered with a collagen sponge and cyanoacrylate
Description: after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
Study NCT03808558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
Study NCT03895476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound covered with a stent
Description: after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
Study NCT00077285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00756639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain X-ray
Description: On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
Study NCT05902793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device: V.A.C. VERAFLO™ Dressing Kit
Description: Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation.
Study NCT05902793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device: Negative pressure wound drainage material
Description: Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation.
Study NCT06058806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physical Therapy
Description: Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00025935 — intervention group
Intervention type: DRUG
Intervention: Lithium
Study NCT03953898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT00077285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00077285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00077285 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03953898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT01548326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: one 40 mg Atorvastatin tablet orally per day for 10 days
Study NCT01548326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one Placebo tablet orally per day for 10 days
Study NCT01985282 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nutrition Status Questionnaires and Physicial Function Test
Description: Nutrition status questionnaires will be administered, Physical functional status will be tested
Study NCT03953898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT01070056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (MINT-TLC)
Description: This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
Study NCT01070056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
Study NCT04086758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion
Study NCT03484234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultimaster stent
Description: Percutaneous coronary intervention with Ultimaster stent for long lesion
Study NCT03484234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience alpine stent
Description: Percutaneous coronary intervention with Xience alpine stent for long lesion
Study NCT00610506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
Study NCT03996837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra uterine infusion of platelet rich plasma
Description: Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
Study NCT01673841 — intervention group
Intervention type: PROCEDURE
Intervention: Relative and absolute cerebral oxygen saturation (rScO2) measurements.
Study NCT04334850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin
Description: The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
Study NCT04334850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual antibiotic treatment
Description: The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
Study NCT04212819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Before Erythrocyte Suspension (ES)
Description: ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
Study NCT04212819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: After Erythrocyte Suspension (ES)
Description: Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
Study NCT03927495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
Study NCT03927495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiotherapy
Description: 3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
Study NCT04487522 — intervention group
Intervention type: PROCEDURE
Intervention: Open retromuscular ventral hernia repair
Description: With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
Study NCT04487522 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic retromuscular ventral hernia repair
Description: With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
Study NCT04487522 — intervention group
Intervention type: DEVICE
Intervention: Robotic-assisted retromuscular ventral hernia repair
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
Study NCT03646643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Atrial fibrillation ablation
Description: The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
Study NCT03646643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary sinus to left atrium connection elimination
Description: Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
Study NCT03489551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haldol
Study NCT01389518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: 1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
Study NCT01389518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
Study NCT03992430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Solution for intravenous (IV) infusion.
Study NCT03992430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eteplirsen
Description: Solution for intravenous (IV) infusion.
Study NCT04251806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neonatal polysomnography
Description: This procedure will allow the detection of sleep-disordered breathing in the neonatal period.
Study NCT04251806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2-year Bayley Exam
Description: This procedure will evaluate neurodevelopmental outcomes.
Study NCT04251806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2-year polysomnography
Description: This procedure will allow the detection of sleep-disordered breathing at 2 years of age.
Study NCT03874598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Description: Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
Study NCT03874598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
Study NCT00763204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Cream, 2%
Study NCT02232191 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23
Study NCT03315754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD Soluble 4 mg/kg
Description: Vascular targeted photodynamic therapy using TOOKAD Soluble
Study NCT02415621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Description: 1000 mg by mouth (PO) every day (QD)
Study NCT01587352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01587352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT04318548 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)
Description: rMenB+OMV will be administered intramuscularly as 1 dose each at day 1 and 61 to subjects in MenB+MenACWY group and MenB group and as 1 dose at day 91 to subjects in MenACWY group, to the deltoid region of the non-dominant arm.
Study NCT04318548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
Description: MenACWY will be administered intramuscularly as 1 dose at day 1 to subjects in MenB+MenACWY group, 1 dose at day 91 for MenB group and as 1 dose at day 1 to subjects in MenACWY group, to the deltoid region of the non-dominant arm.
Study NCT04318548 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intramuscularly as 1 dose at day 91 to subjects in MenB+MenACWY group, 1 dose at day 1 to subjects in MenB group and MenACWY group, to the deltoid region of the non-dominant arm.
Study NCT03553836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Study NCT03553836 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Study NCT03553836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an IV infusion every 3 weeks (Q3W)
Study NCT06698198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine
Description: Suspension for Intramuscular injection
Study NCT03976245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: injection
Study NCT03976245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tofacitinib
Description: tablet
Study NCT03469570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature
Description: Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
Study NCT02986516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized Cohort
Description: Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
Study NCT02986516 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prospective cohort
Description: Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
Study NCT06698198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Suspension for Intramuscular injection
Study NCT05118932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Movement Intervention
Description: There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants.
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m\^2) as an intravenous (IV) infusion.
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m\^2 as an IV infusion.
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m\^2 as an IV infusion.
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m\^2 as an IV infusion.
Study NCT04029688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Chemotherapy
Description: All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
Study NCT02402920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02402920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV